Ionis Pharmaceuticals (IONS) Bullish View Reiterated at BMO Capital Following Spinraza Update
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BMO Capital analyst Do Kim reiterated an Outperform rating and $48 price target on Ionis Pharmaceuticals (NASDAQ: IONS) interim data from the Spinraza (nusinersen) CHERISH study.
Kim commented, "While AVXS-101 narrowed the timeline in SMA infants, we believe these results increased Spinraza's lead in children (Type 2). In addition, FDA feedback suggests Spinraza approval by year-end or 1Q17, ahead of a May 2017 PDUFA. Given the FDA's willingness to expedite SMA drug development and review, we believe approval for Type 2 could shortly follow. We maintain our Spinraza estimates and $48 price target, with potential upside from faster approval in children."
Shares of Ionis Pharmaceuticals closed at $27.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ionis Pharma (IONS): Cutting PT But Improving Fundamentals - BMO
- Credit Suisse Downgrades Himax Technologies (HIMX) to Neutral
- AdvancePierre Foods Holdings (APFH) to Offer 12.5M Shares for Holders
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Related EntitiesBMO Capital, S1, PDUFA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!